Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic Artery FUDR, LV, and DEX vs Systemic 5-FU and LV for Colorectal Cancer Liver Metastases
NCT00002716Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 1996
- Primary completion
- Mar 2006
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of floxuridine and dexamethasone in colorectal cancer (CRC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Overall survival up to 5 years and Time to progression up to 5 years. Started Jan 1996; status: completed.
02
Drugs
floxuridinedexamethasone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00002716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002716.